This study is a prospective, non-interventional, multi-center observational study to evaluate the efficacy and safety of Baroezet Tablet 1/10 mg in Korean patients with dyslipidemia in real-world clinical practice.
Patients who are prescribed Baroezet Tablet according to the physician's clinical judgment will be followed for approximately 24 weeks. The study will assess changes in lipid profiles, including LDL-C, as well as safety outcomes such as adverse events.
Adults aged ≥19 years
Patients diagnosed with dyslipidemia
Patients who require treatment with Baroezet Tablet
Patients who provide written informed consent
Hypersensitivity to study drug components
Active liver disease
Pregnant or breastfeeding women
Patients considered inappropriate by investigator
This study will enroll adult patients aged 19 years or older who are diagnosed with dyslipidemia in routine clinical practice in Korea. Eligible patients are those who require treatment with Baroezet Tablet 1/10 mg based on the physician's clinical judgment and provide written informed consent. Patients will be recruited from multiple centers across Korea in a real-world setting. Treatment decisions, including initiation and continuation of Baroezet Tablet, will be made according to routine clinical practice. Patients with contraindications to the study drug, including hypersensitivity to its components, active liver disease, or pregnancy, will be excluded.
Cohort
Prospective
Not listed
Percent Change in LDL-C from Baseline to Week 24
Percent change in LDL-C levels from baseline to approximately 24 weeks after treatment initiation.
Percent Change in LDL-C at Week 12
Percent change in low-density lipoprotein cholesterol (LDL-C) from baseline to approximately 12 weeks after treatment initiation.
Percent Change in Total Cholesterol (TC)
Percent change in total cholesterol (TC) from baseline to approximately 12 weeks after treatment initiation.
Percent Change in Triglycerides (TG)
Percent change in triglyceride (TG) levels from baseline to approximately 12 weeks.
Percent Change in Total Cholesterol (TC)
Percent change in total cholesterol (TC) from baseline to approximately 24 weeks after treatment initiation.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
